FY2026 EPS Estimate for Sight Sciences Lowered by Analyst

Key Points

• HC Wainwright cut its FY2026 EPS estimate for Sight Sciences to a loss of $0.45 per share from $0.40, while maintaining a Buy rating and $14 price target. The revised estimate is slightly more negative than the consensus forecast of a $0.48 loss.
• Sight Sciences reported quarterly EPS of a $0.12 loss, in line with expectations, while revenue of $24.92 million exceeded the $23.55 million consensus.
• Analyst sentiment is broadly positive: the stock has a Moderate Buy consensus and an average price target of $9.62. Shares opened at $10.08, near their 52-week high of $10.31.

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - HC Wainwright dropped their FY2026 EPS estimates for Sight Sciences in a report released on Thursday, November 5th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.45) for the year, down from their prior forecast of ($0.40). HC Wainwright currently has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Sight Sciences' current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences' Q4 2026 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.02) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.20) EPS.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Sight Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Citigroup lifted their price objective on Sight Sciences from $8.00 to $10.00 and gave the stock a "neutral" rating in a research report on Monday, October 5th. UBS Group boosted their price objective on Sight Sciences from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Piper Sandler restated an "overweight" rating and set a $12.00 target price (up from $9.00) on shares of Sight Sciences in a research report on Thursday. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sight Sciences in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $9.62.

Sight Sciences Price Performance

NASDAQ SGHT opened at $10.08 on Monday. The stock has a market capitalization of $560.25 million, a P/E ratio of -19.38 and a beta of 2.44. Sight Sciences has a 52 week low of $3.38 and a 52 week high of $10.31. The company has a debt-to-equity ratio of 0.71, a quick ratio of 4.72 and a current ratio of 5.04. The stock has a fifty day moving average of $8.72 and a 200-day moving average of $6.09.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $24.92 million for the quarter, compared to the consensus estimate of $23.55 million. Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%.

Insider Buying and Selling at Sight Sciences

In other news, EVP Brenton Taylor sold 2,988 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $8.85, for a total value of $26,443.80. Following the transaction, the executive vice president owned 261,990 shares of the company's stock, valued at $2,318,611.50. This represents a 1.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Paul Badawi sold 29,653 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $268,359.65. Following the completion of the transaction, the chief executive officer directly owned 6,092,819 shares in the company, valued at approximately $55,140,011.95. This trade represents a 0.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 47,646 shares of company stock worth $429,157 over the last quarter. 30.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Sight Sciences during the second quarter worth $16,710,000. Dimensional Fund Advisors LP boosted its stake in Sight Sciences by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company's stock worth $1,288,000 after purchasing an additional 40,346 shares during the period. Renaissance Technologies LLC boosted its stake in Sight Sciences by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company's stock worth $1,106,000 after purchasing an additional 17,458 shares during the period. GSA Capital Partners LLP acquired a new position in Sight Sciences in the 2nd quarter worth $908,000. Finally, Bank of America Corp DE bought a new position in Sight Sciences during the 2nd quarter worth about $520,000. Institutional investors own 55.51% of the company's stock.

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company's portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye's natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.